Otolin-1 as a biomarker for the evaluation of the effectiveness of betahistine treatment for benign paroxysmal positional vertigo

Basit Öğe Kaydı
dc.contributor.authorKaraer, Isil Cakmak
dc.contributor.authorUrhan, Ayca
dc.contributor.authorAkalin, Yahya
dc.date.accessioned2024-08-04T21:00:08Z
dc.date.available2024-08-04T21:00:08Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectiveBenign paroxysmal positional vertigo (BPPV) is the most common vertigo disorder. Betahistine is the most commonly used drug in the treatment of vertigo, however its effect on the inner ear is not fully known. Otolin-1 is an inner ear-specific glycoprotein that can be identified in peripheral blood. The aim of the study was to determine the effect of treatment of betahistine for BPPV on serum otolin-1 levels.MethodsThirty (30) patients with BPPV and 30 healthy controls were enrolled in the study. Serum otolin-1 levels were measured before and 14 days after perioral (po) betahistine treatment in the BPPV group, whereas otolin-1 level was examined once in controls. The efficacy of treatment was evaluated with Dizziness Handicap Index (DHI) and Visual Analog Scale (VAS) in the BPPV group.ResultsOtolin-1 levels were statistically significantly higher in patients with BPPV than controls. In the BPPV group, serum otolin-1 level was found to be statistically significantly lower after betahistine treatment. There was a statistically significantly difference between pre-treatment and posttreatment groups regarding to both DHI and VAS scores.ConclusionSerum otolin-1 can be used as a biomarker in monitoring the effectiveness of treatment of BPPV with betahistine as well as diagnosis of BPPV.en_US
dc.identifier.doi10.1080/21695717.2023.2213957
dc.identifier.endpage322en_US
dc.identifier.issn2169-5717
dc.identifier.issn2169-5725
dc.identifier.issue4en_US
dc.identifier.startpage318en_US
dc.identifier.urihttps://doi.org/10.1080/21695717.2023.2213957
dc.identifier.urihttps://hdl.handle.net/11616/103813
dc.identifier.volume21en_US
dc.identifier.wosWOS:001038073800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofHearing Balance and Communicationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBenign paroxysmal positional vertigoen_US
dc.subjectbetahistineen_US
dc.subjectotolin-1en_US
dc.titleOtolin-1 as a biomarker for the evaluation of the effectiveness of betahistine treatment for benign paroxysmal positional vertigoen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu